(Q36920409)

17 August 2017

1 reference

25 October 2022

Nanomedicines in the treatment of chronic hepatitis C--focus on pegylated interferon alpha-2a (English)

1 reference

delayed-action preparation

17 August 2017

1 reference

6 August 2019

1 reference

19 September 2019

1 reference

7 November 2019

1 reference

20 November 2019

1 reference

20 July 2020

1 reference

30 June 2021

1 reference

inferred from abstract

author name string

Thea Thomas

series ordinal

1

1 reference

17 August 2017

Graham Foster

series ordinal

2

1 reference

17 August 2017

language of work or name

English

0 references

publication date

1 January 2007

1 reference

International Journal of Nanomedicine

17 August 2017

14 references

17 August 2017

23 March 2019

21 March 2019

25 June 2019

6 August 2019

19 September 2019

1 October 2019

7 November 2019

16 November 2019

20 November 2019

1 July 2020

20 July 2020

30 June 2021

25 October 2022

2

1 reference

17 August 2017

1

1 reference

17 August 2017

19-24

1 reference

A health economic model to assess the long term effects and cost-effectiveness of PEG IFN alpha-2a in hepatitis C virus infected patients.

17 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2673816

Use of peginterferon alfa-2a (40 KD) (Pegasys) for the treatment of hepatitis C.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2673816

Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2673816

Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2673816

The prevalence of hepatitis C virus infection in the United States, 1988 through 1994

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2673816

Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2673816

The uses and properties of PEG-linked proteins

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2673816

Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2673816

Peginterferon alfa-2a in patients with chronic hepatitis C.

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2673816

From molecular biology to nanotechnology and nanomedicine

4 September 2018

1 reference

https://api.crossref.org/works/10.2147%2FNANO.2007.2.1.19

American Gastroenterological Association Medical Position Statement: guidelines on intestinal ischemia

31 March 2020

1 reference

https://api.crossref.org/works/10.2147%2FNANO.2007.2.1.19

Alpha-glutathione transferases in HCV-related chronic hepatitis: a new predictive index of response to interferon therapy?

31 March 2020

1 reference

https://api.crossref.org/works/10.2147%2FNANO.2007.2.1.19

AGA technical review on anorectal testing techniques

31 March 2020

1 reference

https://api.crossref.org/works/10.2147%2FNANO.2007.2.1.19

Combination therapy with lamivudine and famciclovir for chronic hepatitis B-infected Chinese patients: a viral dynamics study.

31 March 2020

1 reference

https://api.crossref.org/works/10.2147%2FNANO.2007.2.1.19

Silymarin: What is in the name...? An appeal for a change of editorial policy

31 March 2020

1 reference

https://api.crossref.org/works/10.2147%2FNANO.2007.2.1.19

Persistence of viral replication after anti-HBe seroconversion during antiviral therapy for chronic hepatitis B

31 March 2020

1 reference

https://api.crossref.org/works/10.2147%2FNANO.2007.2.1.19

Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C

31 March 2020

1 reference

https://api.crossref.org/works/10.2147%2FNANO.2007.2.1.19

Effect of the prokinetic agent, erythromycin, in the Richardson ground squirrel model of cholesterol gallstone disease

31 March 2020

1 reference

https://api.crossref.org/works/10.2147%2FNANO.2007.2.1.19

Distribution and tissue uptake of poly(ethylene glycol) with different molecular weights after intravenous administration to mice

31 March 2020

1 reference

https://api.crossref.org/works/10.2147%2FNANO.2007.2.1.19

Nanomedicine: grounds for optimism, and a call for papers

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/17722508

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

EASL International Consensus Conference on Hepatitis C. Paris, 26-28, February 1999, Consensus Statement. European Association for the Study of the Liver

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/17722508

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.2147/NANO.2007.2.1.19

1 reference

17 August 2017

1 reference

17 August 2017

PubMed publication ID

17722508

1 reference